Targeting Cellular and Tissue HIV Reservoirs With Toll-Like Receptor Agonists

Amanda B. Macedo, Camille L. Novis and Alberto Bosque*  

1 Department of Microbiology, Immunology and Tropical Medicine, George Washington University, Washington, DC, United States, 2 Department of Pathology, Division of Microbiology and Immunology, The University of Utah, Salt Lake City, UT, United States

The elimination of both cellular and tissue latent reservoirs is a challenge toward a successful HIV cure. “Shock and Kill” are among the therapeutic strategies that have been more extensively studied to target these reservoirs. These strategies are aimed toward the reactivation of the latent reservoir using a latency-reversal agent (LRA) with the subsequent killing of the reactivated cell either by the cytotoxic arm of the immune system, including NK and CD8 T cells, or by viral cytopathic mechanisms. Numerous LRAs are currently being investigated in vitro, ex vivo as well as in vivo for their ability to reactivate and reduce latent reservoirs. Among those, several toll-like receptor (TLR) agonists have been shown to reactivate latent HIV. In humans, there are 10 TLRs that recognize different pathogen-associated molecular patterns. TLRs are present in several cell types, including CD4 T cells, the cell compartment that harbors the majority of the latent reservoir. Besides their ability to reactivate latent HIV, TLR agonists also increase immune activation and promote an antiviral response. These combined properties make TLR agonists unique among the different LRAs characterized to date. Additionally, some of these agonists have shown promise toward finding an HIV cure in animal models. When in combination with broadly neutralizing antibodies, TLR-7 agonists have shown to impact the SIV latent reservoir and delay viral rebound. Moreover, there are FDA-approved TLR agonists that are currently being investigated for cancer therapy and other diseases. All these has prompted clinical trials using TLR agonists either alone or in combination toward HIV eradication approaches. In this review, we provide an extensive characterization of the state-of-the-art of the use of TLR agonists toward HIV eradication strategies and the mechanism behind how TLR agonists target both cellular and tissue HIV reservoirs.

Keywords: HIV, toll-like receptors, latency-reversal agents, shock and kill, reservoirs

INTRODUCTION

HIV infection is still one of the highest causes of mortality and morbidity worldwide. The introduction of anti-retroviral therapy (ART) in 1996 decreased the mortality due to HIV infection and transformed the disease from deadly to chronic. Cure is still not attainable due to a small reservoir of infected cells that harbor the virus in a latent form and become unrecognizable by the immune system and current therapies (1–5). Several strategies have been proposed to eliminate
this latent reservoir (6). Among these strategies, the “shock and kill” approach rely on the notion that a pharmacological agent that reactivates the latent virus or latency-reversing agent (LRA) in the presence of ART will reduce the latent reservoir and could be followed by two potential outcomes. “Shock and kill” strategies can lead to complete viral eradication. In this case, the final goal is to eliminate all latent viruses. In a way, these strategies will try to echo the Berlin or the London patient, whom underwent remission due to bone marrow transplants and became undetectable for viral reservoirs (7, 8). Another outcome could be that a reduction of the latent reservoir due to the “shock and kill” strategy may be sufficient to allow the immune system control viral replication in the absence of ART (9–12). This has been termed “functional cure” and it is exemplified with the VISCONTI study. In this study, a subset of HIV-infected individuals who started ART early were able to control viremia in the absence of ART (termed Post-Treatment Controllers or PTCs) (11, 12). The authors of this study found a strong association between a low HIV reservoir in blood with the ability of the immune system to control viremia after ART treatment interruption (11).

As of today, several LRAs have been developed and some have reached clinical trials. The first generation LRAs that reached human testing include Valproic Acid (13–18), SAHA (19–21), Romidepsin (22), Panobinostat (23), Broyostatin-1 (24), and Disulfiram (25, 26). However, these LRAs have resulted in limited to no clinical effect on the size of the latent reservoir (27–29). Some potential explanations for the failure of these LRAs are the following. First, the lack of or low reactivation of latent viruses with these LRAs in vivo. Second, the reduced killing of reactivated cells either by the low frequency or compartmentalization of HIV-specific cells on patients under ART, immune exhaustion or the presence of defective proviruses that divert the immune response from the reactivated cells carrying replication competent virus. Third, a survival advantage of latently infected cells (30–36). To that end, strategies that can efficiently reactivate latent HIV in vivo and also enhance immune responses against HIV may overcome these obstacles encountered by the current cure efforts.

Recently, a second generation of LRAs targeting toll-like receptors (TLRs) have reached clinical trials. TLRs are pathogen-recognition receptors (PRRs) capable of sensing small molecular motifs conserved within microbes (37, 38). In addition to their ability to reanimate latent HIV, TLR agonists also increase immune activation and promote antiviral responses (39–44). These combined properties make TLR agonists unique among the LRAs characterized to date.

In 1891, William Coley demonstrated how several bacterial components could be used to treat cancer patients (45). Since then, several TLR ligands are being investigated and in clinical trials to enhance immunity for their use in treatment of cancer (46), viral infection (47), and bacterial infection (48). Several reviews have previously focused in the development and use of TLR agonists for cancer and other diseases (49–51). Here, we provide a comprehensive literature review specifically focused on the development of TLR agonists as LRAs and their potential use of these agonists for HIV eradication purposes.

### TOLL-LIKE RECEPTORS

#### TLRs and Their Ligands

TLRs are transmembrane PRRs that recognize a plethora of molecules present in virus, bacteria, fungi or protozoa such as lipids, proteins, nucleic acids, and carbohydrates (52, 53). PRRs are germline-encoded receptors which function as first line of detection of pathogenic infections and recognize conserved molecular structures called pathogen-associated molecular patterns (PAMPs) (54). PRRs can also recognize soluble molecules released during cell death or damage. These structures are called damage-associated molecular patterns (DAMPs) (55, 56). In humans, there are 10 TLRs that differ both in their location within the cell as well as their cognate PAMP (Figure 1). TLR-1, 2, 4, 5, 6, and 10 are localized on the surface of the cells and recognize PAMPs present at the exterior of bacteria, fungi, and protozoa. On the other hand, TLR-3, 7, 8, and 9 are localized within endosomal structures and recognize nucleic acids derived from bacteria and viruses (53, 57). TLRs recognize their cognate ligand through either homodimers or heterodimers and are expressed in cells of the innate and adaptive immune system (such as dendritic cells, macrophages, granulocytes, T cells, B cells, NK cells, and mast cells) as well as epithelial and endothelial cells [reviewed in (37)].

#### TLRs in the Plasma Membrane

TLR-2 has a broader spectrum of ligand recognition than other TLRs due to its ability to dimerize with other receptors (58, 59). TLR-2 can recognize diacylated lipopeptides in the surface of gram-positive bacteria in conjunction with TLR-6 (60, 61). Whereas, TLR-2 can recognize triacylated lipopeptides present in gram-negative bacteria together with TLR-1 (62). TLR-2 has been shown to also induce signaling as a homodimer when recognizing lipoarabinomannan of *Mycobacterium smegmatis* (LAM-MS) and polysaccharide A of *Bacteroides fragilis* (PSA) (63, 64). Finally, TLR-2 can complex to the c-type lectin Dectin-1 to recognize zymosan, a β-glucan present in yeast cell wall (65). TLR-4 recognizes lipopolysaccharide (LPS), the principal component of gram-negative bacteria, and its truncated versions lipooligosaccharide and lipid A (66). CD14 and MD-2 are also needed for proper TLR-4 signaling (67, 68). TLR-5 recognizes flagellin, the main component of bacterial flagella (69). Lastly, TLR-10 has been an orphan receptor for a long time with no clearly defined ligand (70). TLR-10 has been shown to be involved in triacylated lipopeptides recognition by TLR-2 (71, 72). Recently, TLR-10 has been shown to sense gp41 and other HIV proteins in conjunction with TLR-1 and TLR-2 (73).

#### TLRs in the Endosomal Membrane

Several TLRs are present in endosomes, lysosomes and endolysosomes (74). TLR-3 recognizes double-stranded RNA (dsRNA) generated during viral infections while TLR-7 and TLR-8 both recognize single stranded RNA (ssRNA) (75, 76). Finally, TLR-9 can recognize unmethylated double-stranded DNA derived from both bacteria and viruses (77).
**Synthetic Ligands**

Due to their immunostimulatory properties, the discovery of small molecules that can “mimic” a TLR response is an area of active research. Over the past years, several small molecules have been developed to specifically target TLRs and are being investigated for the treatment of bacterial and viral infections, for cancer immunotherapy and to optimize vaccine efficacy [reviewed in (50, 78, 79)].

Synthetic lipopeptides have been the gold standard TLR-2 ligands. Pam2CSK4 is a synthetic diacylated lipopeptide that engages TLR-2/TLR-6 heterodimers or TLR-2 homodimers (60, 80). Pam3CSK4 is a synthetic triacylated lipopeptide that engages TLR-2/TLR-1 heterodimers (62, 81). Mono-acyl lipopeptides are the minimal structure required for TLR-2 activity (82). Guan and colleagues identified a series of compounds with a similar core structure consisting of 3-carboxylbenzothiophene linked via a carbonothioyl amino bridge to an anilino group (83). Further structure-activity relationship (SAR) studies have yielded an optimized novel compound termed CU-T12-9 (84). This compound has shown higher efficacy than the original compound and shows a specificity toward TLR-2/TLR-1 heterodimers over TLR-2/TLR-6 heterodimers (84). Using structure-based virtual screening of over 10.5 million compounds, Chen and colleagues identified ethyl 2-(4-methylpiperazine-1-carboxamido)-5,6-dihydro-4H-cyclopenta[b]thiophene-3-carboxylate (SMU127) as a specific TLR-2/TLR-1 heterodimer ligand (85). Recently, the same group has developed 2-(1-(2-(Methylamino)-5-nitrophenyl)-1H-imidazol-4-yl)-5-(trifluoromethyl)phenol (SMU-Z1) as a specific TLR-2/TLR-1 heterodimer ligand (86). Finally, a screening in PMA-differentiated THP-1 cell line of nearly 100,000 compounds identified diprovocims as inducers of TLR-2 and TLR-1 receptor dimerization and activation in the low pM range (87).
The main synthetic ligand used for TLR-3 is polyinosinic-polycytidylic acid [poly(I:C)]. Poly(I:C) mimics dsRNA and it is formed of a strand of inosine poly(I) homopolymer annealed to a strand of cytidine poly(C) homopolymer. The antiviral and antitumoral activities of Poly(I:C) were described in the 1960’s but it was not characterized as a TLR-3 agonist until the early 2000’s (75). Other derivatives of Poly(I:C) have been developed such as a combination of polyinosinic-polycytidylic acid and poly-L-lysine (PolyICLC/Hiltonol®), or the introduction of uridine in the Poly(I:C) strand (poly(I:C12U)/rintatolimod/Ampligen®), or Polyadenylic–polyuridylic acid [poly(A:U)] (88–90).

Monophosphoryl lipid A (MPL) is a detoxified form of the TLR4 agonist LPS from Salmonella minnesota that retains immunostimulatory properties but lacks the toxic effects of LPS (91). RC599 is a synthetic mimetic of MPL derived from aminoalkyl glucosaminide 4-phosphate (92). Both, MPL and RC599 have been shown to be efficient adjuvants and promote CD4 T cell responses (93). MPL has been used in a number of complex adjuvants included in human vaccines (Supervax®, Cervarix, Melacine®, Stimuvax) [reviewed in (94)]. Other lipid A mimetics (AS04, GLA-SE, GS1795091, and OM-174) have been developed as vaccine adjuvants and are in licensed vaccines or in Phase I or II clinical trials as anticancer therapeutics [reviewed in (95)].

The polypeptide CBLB502 (Entolimod) derived from Flagellin is a potent TLR-5 ligand under extensive investigation as vaccine adjuvant, cancer and ischemia (96–99).

Imiquimod is an imidazoquinoline amine analog to guanosine that specifically activates TLR-7 (100). Several other agonists derived of imidazoquinoline have been developed that target TLR-7 such as Gardiquimod™ and PF-04878691 [also known as 852A or 3M-001] (101, 102), or to target TLR-7 and TLR-8 simultaneously such as CL075, CL097, or Resiquimod (also known as R-848) (103–105). In addition, guanosine analogs such as Loxoribine have been generated as specific TLR-7 ligands (106). ANA975 and ANA773, also guanosine analogs, are prodrugs derived of the TLR-7 agonist isatoribine (107, 108). CL264 and SM360320 are derivatives of 9-benzyl-8 hydroxyadenine that have been shown to stimulate TLR-7

![Figure 2](image-url)
(109, 110). Finally, GS-9620 (Vesatolimod) and its close analog GS-986 are also a 9-benzyl-8 hydroxyadenine derivatives that targets TLR-7 with higher activity than CL264 (41, 42, 111).

All the synthetic TLR-9 ligands generated to date are derived from CpG oligodeoxynucleotides (CpG ODNs). CpGs ODNs can be classified into three classes (A, B, or C) that differ in their structure as well as their immunostimulatory properties (112, 113). Among others, CpG ODNs include CPG10101, IMO-2125, SD-101, CpG7909 (ProMune), MGN1703 (Leftolimod) (114–118).

Finally, a series of synthetic TLR ligands that covalently link two or more TLR ligands are under investigation. These multi-TLR ligands have been designed to enhance immune responses through the synergistic activation of two or more TLRs with different downstream pathways (42, 119).

**TLR Signaling Pathway**

TLRs are type I transmembrane glycoproteins composed of a leucine-rich-repeat (LRR) motifs on the extracellular or endosomal domain that mediates ligand recognition and the Toll/IL-1R (TIR) in the cytoplasmic domain responsible for signaling (120). The signaling cascades following TLR activation involves multiple steps. Adaptor proteins such as myeloid differentiation primary-response protein 88 (MyD88), TIR-domain containing adaptor protein (TIRAP, also known as MAL), TIR-domain containing adaptor protein inducing IFN-β (TRIF) and TRIF-related adaptor molecule (TRAM) are recruited to the TIR domain after interaction of PAMPs to their cognate TLR (Figure 2).

With the exception of TLR-3, all TLRs signal through the MyD88-dependent pathway. In the MyD88-dependent pathway, TLR-2 and TLR-4 require TIRAP in order to recruit MyD88 to start signal transduction while TLR-5, TLR-7, TLR-8, and TLR-9 initiate signaling using uniquely MyD88 (121, 122). After recruitment of MyD88, a complex is formed with interleukin-1 receptor-associated kinase-1 (IRAK1) and IRAK4. IRAK1 is phosphorylated and associates with TNF receptor-associated factor 6 (TRAF6), which activates transforming growth factor-β-activated kinase 1 (TAK1), also known as mitogen-activated protein kinase kinase kinase 7 (MAP3K7). TAK1 activates, by phosphorylation, two routes; the IkB kinase—nuclear factor κB nuclear translocation. Mutations in κB targeting the HIV LTR abolished PDD-induced HIV expression (123).

In the MyD88-independent pathway, TRIF is recruited to TLR-3 to initiate signaling (125). Besides TLR-3, TLR-4 can be endocytosed and signal through TRIF using the adaptor molecule TRAM (126, 127). TRAF6 and TRAF3 are recruited to TRIF. While TRAF6 engages IKK and MAPK, leading to the activation of NF-κB, AP-1, and IRF7; TRAF3 recruits TBK1/IKK-ε complex that activates IRF3 culminating in IFN-β expression (Figure 2) (128, 129).

### TOLL-LIKE RECEPTOR AGONISTS AS LATENCY-REVERSING AGENTS

**In vitro Studies**

The importance of TLRs in the physiopathology of HIV was first postulated after observations on increased plasma viral loads seen in HIV-infected individuals exposed to vaccination regimens, suffering of opportunistic bacterial infections or sexually transmitted diseases, or had translocation of microbial products from the gut (130–138). Early studies have shown that PAMPs and their corresponding microorganisms transactivate the HIV long-terminal repeat (LTR) promoter. For example, it was described that purified protein derivative (PPD) of *Mycobacterium tuberculosis* increased viral mRNA expression in HIV infected monocytes (139). Furthermore, monocytic cell lines stimulated with live *M. tuberculosis* or lipomannan (LAM) increased p24 expression by 3-fold and enhanced HIV LTR transcription (140). Additionally, it has been shown that both *M. tuberculosis* PPD from the H37Ra strain and the mycobacterial major cell wall component mannosylated LAM (ManLAM) activated transcription of HIV in the T cell line Jurkat. ManLAM-induced HIV gene expression was mediated via protein kinases that culminated in NF-κB nuclear translocation. Mutations in the NF-κB binding sites in the HIV LTR abolished PDD-induced HIV expression (141, 142). These findings suggested that microbial products could be inducing HIV transcription. The latter discovery of TLRs as sensors of these microbial products suggested the idea that TLR agonists could reactivate latent HIV and could be potential LRAs.

Subsequently increasing number of reports have demonstrated the role of specific TLR agonists as latency reversing agents in *vitro*. Equils and colleagues transfected human dermal endothelial cells with an LTR luciferase construct and showed that stimulation of TLR-4 with LPS leads to NF-κB activation and transactivation of HIV-LTR (143). However, the effect of LPS in the reactivation of the HIV promoter in T cells has been disputed by other groups (144–146). These divergent results could be explained by the use of contaminated LPS formulations with other PAMPs, like bacterial lipopeptides. Other possible reasons for the discrepancy could be variation in the cell type used in each study, since different cells respond differently to TLR agonists, the cell culture environment, which component could escalate or impair an agonists effect, and/or disparities in TLR-4 binding affinity to LPS from different bacteria. Recently, LPS has been shown to reactivate latent HIV in macrophages isolated from the urethra of patients under ART (147).

The TLR-9 agonist CpG ODNs has been shown to activate HIV replication in the chronically infected human cell lines.
U1 and ACH2 in an NF-κB dependent manner (148, 149). Furthermore, DNA from *F. nucleatum* increased HIV promoter activity through TLR-9 signaling in the THP89GFP cell line (144). Recently, the TLR9 MGN1703 has been shown to induce HIV RNA release in peripheral blood mononuclear cells (PBMCs) from aviremic HIV-infected donors on antiretroviral therapy (ART) (150).

Mycobacteria have been shown to induce HIV transcription in a TLR-2 dependent manner. Bhat et al. observed that the *M. tuberculosis* and *M. smegmatis* proline-proline-glutamic acid protein Rv1168c (PPE17) interacts with TLR-2 resulting in activation of NF-κB and HIV transactivation in the human monocyte cell line THP1 (151). Our group has shown that the TLR-2 agonists Pam2CSK4 and Pam3CSK4 have latency reversal activity in CD4 T cells from aviremic HIV-infected participants and in a primary TCM cell model of latency (42, 146, 152). Finally, the component of the *M. tuberculosis* membrane phosphatidylinositol mannoside 6 (PIM6) as well as whole bacteria in co-culture reactivated HIV in a primary TCM cell model of latency. As for previous studies with *M. tuberculosis*, viral reactivation was dependent on TLR-2 (153).

R-848, a TLR-7/8 agonist, induced p24 expression in the latently infected monocyte cell lines U1 and OM10 (154). Furthermore, a combination of the PKC agonist and LRA prostratin with a TLR-8 agonist 3M-002 was tested in a coculture of latently infected cells (J-Lat) and monocyte-derived dendritic cells (MDDCs). The combination of prostratin and 3M-002 resulted in greater reactivation of HIV latency in J-Lat than each compounds alone. This synergistic interaction was dependent on TNF-α and on MDDC-T cell interactions (155).

Flagellin, the structural protein in bacterial flagella and a TLR5 agonist, has been shown to reactivate latent HIV in J-Lat, a transformed cell line latently infected with HIV derived of Jurkat (146, 156, 157). Thibault and colleagues also shown activity of flagellin in central memory T cells previously infected with a VSV-G pseudotyped NL43. However, resting CD4 T cells from aviremic patients, when challenged with flagellin, failed to elicit detectable levels of viral gene expression (157).

The TLR-3 agonist Poly(I:C) has been shown to reactivate latent HIV via NF-κB and JNK in the monocyte cell line U87 that contains a stably integrated and silent copy of the HIV LTR promoter linked to the chloramphenicol acetyltransferase (CAT) gene (158).

The selective TLR-7 agonist GS-9620 induced extracellular HIV RNA release in the supernatants of PBMCs isolated from HIV-infected participants on ART but not in purified CD4 T cells (159). In this study, Tsai and colleagues attributed this viral reactivation to type I IFN produced by pDCs. Therefore, this last finding suggests two complementary mechanisms of latency reversal mediated by TLR agonists. One that requires a subset of immune cells to be activated with the TLR agonist and these cells release soluble factors with latency reversal activity. And a second mechanism in which the TLR agonists have a direct effect on latently infected CD4T cells. Based on this idea, we have recently characterized the mechanisms of viral reactivation mediated by the TLR-2 agonist Pam2CSK4 and the TLR-7 agonist GS-9620 and compared with that of synthetic dual TLR-2 and TLR-7 agonists (dual TLR-2/7 agonists). We found that TLR-2 and TLR-7 agonists reactivate latency by two distinct and complementary mechanisms. TLR-2 agonists reactivate HIV by directly inducing NF-κB activation in memory CD4 T cells, while TLR7 agonists induced the secretion of soluble factors that can reactivate latent HIV in CD4 T cells. Our results suggests that TNF-α but not type-1 IFN secreted by monocytes and plasmacytoid dendritic cells (pDCs) promotes viral reactivation in CD4 T cells (42).

TLR agonists have also shown to reactivate latent HIV in other cell subsets besides CD4 T cells and monocytes/macrophages. Poly (I:C) and bacterial ribosomal RNA induced HIV reactivation through TLR-3 in a latency model using immortalized human primary microglia with simian virus-40 (SV40) large T antigen and human telomerase reverse transcriptase (160). Furthermore, stimulation with TLR-2, TLR-4, or TLR-9 agonists induced HIV replication in a primary latency model using human progenitor mast cells (161).

**In vivo Studies: From Small Animals to Clinical Trials**

Mouse models have been a tool to study the role of TLR agonists on the pathogenesis of HIV. Initial studies were done using a transgenic mouse model that contains intact copies of HIV proviral DNA (162). Infection of these animals with *Mycobacterium avium* or *Toxoplasma gondii* increased viral production in monocytes/macrophages (163, 164). Using *ex vivo* spleens from these transgenic mice, Equils and colleagues demonstrated that ligands for TLR-2 (soluble Mycobacterium tuberculosis factor or STF), TLR-4 (LPS), and TLR-9 (CpG) increased viral production and that combination of LPS with either STF or CpG increased viral production in an additive manner (165). Furthermore, Bafica and colleagues crossed this HIV transgenic mouse with either a TLR-2-deficient or a control mouse to investigate the role of TLR-2 in the activation of HIV expression. Culture filtrate proteins, phosphatidylinositol mannoside from *M. tuberculosis* and the synthetic lipopeptide Pam3CSK4 induced p24 expression in spleen cells from HIV transgenic mouse expressing TLR-2 but not the TLR-2 deficient mice (166).

Several studies have specifically looked at the effects of TLR agonists on the latent reservoir *in vivo* (Table 1). A study using a humanized mice model of HIV latency demonstrated that the TLR-3 agonist poly(I:C) can reactivate latent HIV *in vivo* (167). In this study, the co-administration of poly(I:C) with a vaccination regimen including recombinant anti-human CD40 antibody fused to 5 HIV peptide regions (αCD40.HIV5pep) reduced the levels of cell-associated HIV DNA and delayed 1 week viral rebound after ART interruption in these animals (167). The selective TLR-7 small-molecule agonist GS-9620 has demonstrated antiviral activity in animal models of hepatitis B virus, good safety profiles and has progressed to clinical testing (171–173). As such, TLR-7 agonists have also been tested as LRAs in SIV-infected rhesus macaques. So far, there has been 4 different studies on the administration of GS-9620 or its analog GS-986 in infected macaques under suppressive ART.
## TABLE 1 | Summary of in vivo studies using TLR ligands as LRAs.

| Administration | Study arms | Specie | Viral blips | Effects on reservoir | References |
|----------------|------------|--------|-------------|----------------------|------------|
| Poly I:C (TLR3) | Two doses 2.5 weeks apart, half IP half IM | PBS Poly I:C uCD40.HIV5pep/ Poly I:C | NRG hu-mice | Yes (US/7) Reduction on cell-associated DNA in lymphoid tissue (4/4) Delayed rebound (αCD40.HIV5pep/Poly I:C 1 week) | (167) |
| Poly-ICLC (TLR3) | Two consecutively daily doses, SC | Randomize (3:1) vs placebo | Human | 0/12 Reduction on cell-associated DNA (0/12) | (168) |
| GS-986 (TLR7) | Ten doses two weeks apart, OG | Sham Ad26/MVA GS-986 GS-986/Ad26/MVA | Rhesus macaque | Sham (0/9) Ad26/MVA (0/9) GS-986 (0/9) GS-986/Ad26/MVA (1/9) Reduction on cell-associated DNA in lymph nodes week 70 (Sham 1/9, Ad26/MVA 1/9, GS-986 4/8, GS-986/Ad26/MVA 6/8) Reduction on cell-associated DNA in PBMCs week 70 (Sham 3/9, Ad26/MVA 9/9, GS-986 4/8, GS-986/Ad26/MVA 6/8) Virologic control (Sham 0/9, Ad26/MVA 0/9, GS-986 0/8, GS-986/Ad26/MVA 3/8) | (39) |
| GS-9620 (TLR7) | Ten doses two weeks apart, OG | Sham PGT121 GS-9620 GS-9620/PGT121 | Rhesus macaque | Sham (0/11) PGT121 (0/11) GS-9620 (0/11) GS-9620/ PGT121 (0/11) Reduction of viral DNA in lymph nodes week 120 (Sham 4/11, PGT121 7/11, GS-9620 3/11, GS-9620/PGT121 11/11) Virologic control (Sham 0/11, PGT121 3/11, GS-9620 1/11, GS-9620/PGT121 5/11) | (40) |
| GS-986 (TLR7) | Dose escalation 2 weeks apart, OG | Sham GS-986 | Rhesus macaque | Sham (0/3) GS-986 (4/4) Reduction of viral DNA in memory CD4 T cells from PBMCs (3/4), LNMCs (4/4) and GMMC (4/4) | (41) |
| GS-9620 (TLR7) | Ten doses 2 weeks apart, OG | Sham GS-9620 0.05 mg/kg GS-9620 0.1 mg/kg GS-9620 0.15 mg/kg | Rhesus macaque | Sham (0/3) GS-9620 0.05 mg/kg (3/3) GS-9620 0.1 mg/kg (3/3) GS-9620 0.15 mg/kg (3/3) Reduction of viral DNA in memory CD4 T cells from PBMCs (Sham 2/2, GS-9620 0.05 mg/kg 3/3, GS-9620 0.1 mg/kg 3/3, GS-9620 0.15 mg/kg 3/3) Reduction of viral DNA in memory CD4 T cells from LNMCs (Sham 1/2, GS-9620 0.05 mg/kg 1/3, GS-9620 0.1 mg/kg 2/3, GS-9620 0.15 mg/kg 1/3) Reduction of viral DNA in memory CD4 T cells from GMMC (Sham 0/2, GS-9620 0.05 mg/kg 2/3, GS-9620 0.1 mg/kg 3/3, GS-9620 0.15 mg/kg 3/3) Virologic control (Sham 0/2, GS-9620 0.05 mg/kg 0/3, GS-9620 0.1 mg/kg 1/3, GS-9620 0.15 mg/kg 1/3) | (41) |
| GS-9620 (TLR7) | First course of twelve doses 2 weeks apart, OG Second course of five dose 2 weeks apart, OG | Sham GS-9620 | Rhesus macaque | Sham (0/2) GS-9620 (0/4) No effects in viral HIV DNA | (169) |
| GS-9620 (TLR7) | Tablet(s) administered orally once every 2 weeks | Randomized, blinded, placebo-controlled dose-escalation study | Human | Completed trial Completed trial NCT02858401 | (Continued) |
Macedo et al. TLR Agonists as LRAs

The first study combined the therapeutic vaccine Ad26/MVA (recombinant adenovirus serotype 26 (Ad26) prime, modified vaccinia Ankara (MVA) boost) with GS-986. They found that this combination resulted in decreased levels of viral DNA in lymph nodes and peripheral blood, and improved virologic control and delayed viral rebound following discontinuation of antiretroviral therapy (39). In another study from the same group, GS-9620 was combined with the V3 glycan-dependent bNAb PGT121 in rhesus monkeys during ART (40). This combination delayed viral rebound after ART discontinuation. Interestingly, 5 out of 11 monkeys did not show viral rebound even after CD8-depletion or adoptive transfer of PBMCs and LNMCs into naive monkeys (40). In a third study, repeated administration of GS-9620 or its analog G-986 to SIVmac251-infected rhesus macaques under ART was associated with transient plasma viremia that peaked 24 to 48 h after dosing (41). Furthermore, TLR-7 agonists induced a reduction in cell-associated SIV DNA in sorted memory CD4 T cells obtained from peripheral blood, gastrointestinal mucosa and lymph nodes (41). Finally, a recent study also evaluated the effects of repeated doses of the TLR7 agonist GS-9620 in SIV-infected rhesus macaques receiving ART (169). The rhesus macaques that received GS-9620 during ART presented with virologic changes and differences in plasma cytokines such as IFN-α and IL-1RA, and changes in CD8, NK and macrophage activation. In contrast with the study from Lim and colleagues, GS-9620 did not result in a measurable increase in plasma viremia or changes in viral RNA–to–viral DNA ratio in PBMCs or tissues, nor decreases in viral DNA in PBMC or tissues (169). Several differences can account for the discrepancies in these two studies. First, ART was initiated at different times after initial infection (65 vs. 13 days). Second, GS-9620 was administrated at different times post-ART initiation (60 vs. 75 weeks). Third, the SIV strain used in each study were different (SIVmac251 vs. SIVmac239X). Forth, the route of inoculation was also different (intrarectally vs. intravenously). All of these differences could lead to variations in the formation of viral reservoirs and their sensitivity to TLR-7 agonists. Further studies are warranted to fully understand the discrepancies of these two studies.

TLR agonists have also reached clinical testing in ART-suppressed participants (Table 1). The TLR-9 agonist CpG-ODN 7909, a class B CpG ODN, was administered as adjuvant in HIV-infected individuals (174). Interestingly, those participants receiving the TLR9 agonist as adjuvant in the immunization protocol had some decrease in the HIV proviral reservoir compared the control group (170). This led to the idea of using TLR-9 agonists to reduce the latent reservoir. As such, two different clinical trials aimed toward HIV eradication have been done using the TLR-9 ligand MGN1703. In the first clinical trial, a single-arm, open-label study in which 15 (13 male, 2 female) virologically infected individuals on ART received 60 mg MGN1703 subcutaneously twice weekly for 4 weeks (43). In this study, they characterized pDC, NK, and T-cell activation using flow cytometry on baseline and after 4 weeks of treatment. Additionally, HIV transcription was quantified by measuring plasma HIV RNA. MGN1703 treatment...
increased the activation of pDCs, upregulated levels of cytokines, and enhanced activation of cytotoxic NK cells and effector CD8+ T cells. Furthermore, treatment with MGN1703 induced plasma HIV RNA blips up to >1,500 copies/mL in 6 of 15 participants (43). From this trial, biopsies from sigmoid colon were collected from 11 participants. Increased in solely type-1 interferon response but not a broad inflammatory response was observed in intestinal mononuclear cells. Interestingly, increased transcription of either TLR9 or IFNARI before MGN1703 administration was associated with improved efficacy in eliminating HIV DNA-containing cells in the intestine during the course of treatment (175). In the second clinical trial, the same group enrolled HIV-infected individuals on ART for an exploratory, single-arm clinical trial that tested the safety and immune enhancement effects of 24-weeks of MGN1703 (60 mg 2 weekly) therapy (44). A total of twelve individuals completed the treatment phase and nine underwent analytical treatment interruption (ATI). MGN1703 led to potent T-cell activation and increased HIV-specific T-cell responses, however there were no changes in CD4 T cells containing viral DNA nor differences in the time to rebound after ATI. In this study, a single patient was able to control viremia for 150 days after ATI. This participant had strong HIV-specific cellular and antibody-mediated immune responses, however as the study did not contain a placebo arm, the delayed viral rebound cannot exclusively be associated to MGN1703 treatment (44). The TLR-3 agonist Poly-ICLC (Hiltonol®) has also been tested in a randomized, placebo-controlled, double-blinded trial in ART-suppressed participants (168). In this study, participants received two daily doses of Poly-ICLC subcutaneously. Both, Poly-ICLC and placebo control were observed for adverse events, immune activation, and viral replication. As for other TLR agonists, Poly-ICLC administration lead to transient innate immune stimulation without generalized immune activation. While no effects of Poly-ICLC in reversing HIV latency or on the size of the viral reservoirs were observed; Poly-ICLC was reported safe and well-tolerated (168). Finally, the TLR7 agonist GS-9620 is currently being evaluated in clinical trials in HIV infected controllers (NCT03060447) and in those on suppressive ART (NCT02858401). These studies will provide information regarding safety and biological activity, including their impact on viral reservoirs, in HIV-infected patients.

MODULATION OF HIV-HOST IMMUNE RESPONSES BY TLR STIMULATION

Besides their potential ability to reactivate latent HIV, TLR agonists have been shown to have immunostimulatory and antiviral properties to modulate anti-HIV immune responses.

The TLR-2 agonist Pam3CSK4 has been shown to prime latently-infected CD4 T cells for CD8 T cell recognition (176). We have characterized that TLR-2 and dual TLR-2/7 agonists, besides reactivating latent HIV, can activate NK cells and induce IL-22. We demonstrated a protective role for IL-22 in both cell-free and cell-to-cell HIV infection of CD4 T cells (42). Whether TLR-2 agonists enhance the ability of NK cells to kill HIV-infected cells has not been demonstrated yet. Furthermore, the dual TLR-2/7 agonist PamadiFectin has been shown to enhance humoral responses in a mouse model immunized with p24 coupled to nanoparticles (119).

The TLR-3 agonist poly(I:C) enhanced the generation of HIV-specific T cell responses in BALB/c mice and in humanize mouse vaccination models (167, 177). In vitro, the TLR-7 agonist GS-9620 has been shown to both inhibit HIV replication in an IFN-α-mediated mechanism as well as enhance the anti-HIV activity of CD8 T and NK cells (159, 178). The TLR-7/8 agonist 3M-012, an analog of R-848, has been given as vaccine adjuvant in combination with HIV Gag antigens to non-human primates. The addition of 3M-012 to the Gag vaccine substantially enhanced Gag-specific T helper 1 and CD8 T cell responses compared to animals given the Gag protein alone (179). Furthermore, TLR-7/8 activation through ssRNA or R-848 interfered with HIV replication cycle in lymphocyte cultures (154). In addition, The TLR-7/8 agonists 3M-002 and R-848 were able to promote HIV control in vitro in HIV-infected PBMCs through the activation of CD8 T cells and NK cells (180).

A randomized controlled vaccine trial conducted with 95 HIV-infected subjects investigated the impact of TLR-9 agonist as an adjuvant for pneumococcal vaccine. The trial showed that the TLR-9 agonist, CpG-ODN 7909, enhanced vaccine immunogenicity in the experimental group compared with the control group (174). Post-hoc analyses of the vaccine trial confirmed that patients that received TLR-9 ligand as adjuvant expressed more CD107a and macrophage inflammatory protein 1β (MIP1β) markers in CD8 T cells. The increase in these markers was associated with a reduction in HIV proviral load (170). Furthermore, the TLR-9 agonist CpG-ODN 2216 has been shown to activate NK cells in a pDC-mediated mechanism and enhance NK lysis of autologous HIV-infected CD4 T cells (181). In addition, TLR ligands such as Imiquimod (TLR-7), R-848 (TLR-7/8), CpG ODN (TLR-9), and Poly(I:C) (TLR-3) have been also shown to enhance the generation of HIV-specific CD8 T cells in vitro (182).

CONCLUDING REMARKS

The use of TLR ligands as LRAs has shown promising results in efforts toward HIV eradication either alone or in combination with other therapeutic strategies because of their ability to reactivate latent HIV, to enhance immune responses and promote antiviral responses. Several TLR agonists are under investigation both in pre-clinical models of HIV latency as well as in clinical trials (Figure 1). These preclinical and clinical studies have shown a wide variety of response even in studies using the same TLR agonists (Table 1). Why such differences are currently unknown. Based on these studies, we can speculate several factors that may be influencing the response to TLR agonists including the time of ART initiation, the length of ART treatment, the cellular composition of the latent reservoir, or the strain of SIV or HIV. There are also other factors that may influence the activity of these agonists that will need to be considered in future cure strategies. First, TLRs contain polymorphisms that influence their activity (183, 184). How these polymorphisms...
affect the efficacy of different TLR ligands in HIV eradication approaches has not been characterized. Second, it is well-known that biological sex influences the responses of certain TLRs, in particular TLR-7 (185, 186). The in vivo evaluation of GS-9620 or other TLR-7 agonists will need to take this into account. As research progresses, emphasis also needs to be done in understanding whether these TLR agonists can reach all the different tissue compartments where HIV may hide, including lymph nodes, intestinal mucosal, and brain [reviewed in (187–191)]. Furthermore, HIV has been shown to reside latent in other cell types besides CD4 T cell (147, 192). As such, it is possible that a single TLR agonist may not be sufficient to reactivate all latent virus present in different cellular compartments as the expression of TLRs differs among different cell subsets. Additional research is warranted to fully understand which TLR agonists reactivate latent HIV in each cell compartment. Also, it will be important to address whether reactivation is due to a direct targeting of the TLR in the reservoir cell or whether other soluble factors secreted by other cells are required for efficient viral reactivation. The mechanisms involved in HIV latency are complex and involve a plethora of cellular factors as well as epigenetic mechanisms (193). As such, TLR agonists may need to be combined with other LRAs with different mechanisms of action to efficiently reactivate all latent viruses. Finally, recent studies using animal models suggest the use of additional strategies, such as bNAb, might be required to generate meaningful remission. Therefore, it is important to continue the investigation of TLR agonists as potential adjuvants for novel HIV cure strategies.

**AUTHOR CONTRIBUTIONS**

AM, CN, and AB contributed to the conception of the review and wrote the first draft of the manuscript. All authors contributed to manuscript revision, read, and approved the submitted version.

**FUNDING**

The work in AB’s lab is currently supported by the National Institute of Health grants R01-AI124722, R21/R33-AI116212, R01-AI147845, UM1-AI1126617, and P30-A1117970.

---

**REFERENCES**

1. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, Baseler M, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. *Proc Natl Acad Sci USA.* (1997) 94:13193–7. doi: 10.1073/pnas.94.24.13193

2. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaison RE, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. *Science.* (1997) 278:1295–300. doi: 10.1126/science.278.5341.1295

3. Wong JK, Hezarche M, Gunhard HF, Hafvrir DV, Ignacio CC, Spina CA, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. *Science.* (1997) 278:1291–5. doi: 10.1126/science.278.5341.1291

4. Brenchley JM, Hill BL, Ambrozak DR, Price DA, Guenaga FJ, Casazza JP, et al. T-cell subsets that harbor human immunodeficiency virus (HIV) in vivo: implications for HIV pathogenesis. *J Virol.* (2004) 78:1160–8. doi: 10.1128/JVI.78.3.1160-1168.2004

5. Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. *Nat Med.* (2009) 15:893–900. doi: 10.1038/nm.1972

6. Barouch DH, Deeks SG. Immunologic strategies for HIV-1 remission and eradication. *Science.* (2014) 345:169–74. doi: 10.1126/science.1255512

7. Gupta RK, Abdul-Jawad S, McCoy LE, Mok HP, Peppa D, Salgado M, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. *Nature.* (1997) 388:244–8. doi: 10.1038/388244a0

8. Hutter G, Nowak D, Mossner M, Ganepola S, Mussig A, Allers K, et al. Immunologic strategies for HIV-1 remission following CCR5Delta32/Delta32 haematopoietic stem-cell transplantation. *Nature.* (1997) 388:244–8. doi: 10.1038/388244a0

9. Lehrman G, Hogue IB, Palmer S, Jennings C, Spina CA, Wiegand A, et al. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. *Lancet.* (2005) 366:549–55. doi: 10.1016/S0140-6736(05)67098-5

10. Routy JP, Tremblay CL, Angel JB, Trottier B, Rouleau D, Baril JG, et al. Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study. *HIV Med.* (2012) 13:291–6. doi: 10.1111/j.1468-1293.2011.00975.x

11. Sagot-Lerolle N, Lamine A, Chaix ML, Boufassa F, Aboulker JP, Costagliola D, et al. Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir. *AIDS.* (2008) 22:1125–9. doi: 10.1128/JVI.78.3.1160-1168.2004

12. Siliciano JD, Lai J, Callender M, Pitt E, Zhang H, Margolick JB, et al. Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. *J Infect Dis.* (2007) 195:833–6. doi: 10.1086/511823

13. Archin NM, Bateson R, Tripathy MK, Crooks AM, Yang KH, Dahl NP, et al. Polyfunctional HIV-specific T cells and can induce remission. *J Antimicrob Chemother.* (2012) 13:291–6. doi: 10.1111/j.1468-1293.2011.00975.x

14. Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, et al. Identification of a reservoir for HIV-1 in patients on suppressive antiretroviral therapy. *PLoS Pathog.* (2013) 9:e1003211. doi: 10.1371/journal.ppat.1003211

15. Samri A, Bacchus-Souffan C, Hocqueloux L, Aretand-Fenoel V, Descours B, Theodorou L, et al. Polyfunctional HIV-specific T cells in Post-Treatment Controllers. *AIDS.* (2016) 30:2299–302. doi: 10.1097/QAD.0000000000001195

16. Archin NM, Cheema M, Parker D, Wiegand A, Bosch RJ, Coffin JM, et al. Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection. *PLoS ONE.* (2010) 5:e9390. doi: 10.1371/journal.pone.0009390

17. Archin NM, Eron JJ, Palmer S, Hartmann-Duff A, Martinson JA, Wiegand A, et al. Valproic acid without intensified antiretroviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. *AIDS.* (2008) 22:1131–5. doi: 10.1097/QAD.0b013e328286fedf4

18. Siliciano JD, Lai J, Callender M, Pitt E, Zhang H, Margolick JB, et al. Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. *J Infect Dis.* (2007) 195:833–6. doi: 10.1086/511823

19. Archin NM, Eron JJ, Palmer S, Hartmann-Duff A, Martinson JA, Wiegand A, et al. Valproic acid without intensified antiretroviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. *AIDS.* (2008) 22:1131–5. doi: 10.1097/QAD.0b013e328286fedf4

20. Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, et al. Identification of a reservoir for HIV-1 in patients on suppressive antiretroviral therapy. *PLoS Pathog.* (2013) 9:e1003211. doi: 10.1371/journal.ppat.1003211

21. Samri A, Bacchus-Souffan C, Hocqueloux L, Aretand-Fenoel V, Descours B, Theodorou L, et al. Polyfunctional HIV-specific T cells in Post-Treatment Controllers. *AIDS.* (2016) 30:2299–302. doi: 10.1097/QAD.0000000000001195

22. Archin NM, Cheema M, Parker D, Wiegand A, Bosch RJ, Coffin JM, et al. Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection. *PLoS ONE.* (2010) 5:e9390. doi: 10.1371/journal.pone.0009390
vivo. PLoS Pathog. (2015) 11:e1005142. doi: 10.1371/journal.ppat.1005142

23. Rasmussen TA, Tolstrup M, Brinkmann CR, Olesen R, Erikstrup C, Solomon A, et al. Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single-group, clinical trial. Lancet HIV. (2014) 1:e13–21. doi:10.1016/S2352-3018(14)70014-1

24. Gutierrez C, Serrano-Villar S, Madrid-Elena N, Perez-Elias MJ, Martin ME, Barbas C, et al. Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy. AIDS. (2016) 30:1385–92. doi:10.1097/QAD.0000000000001064

25. Elliott JH, McMahon JH, Chang CC, Lee SA, Hartogensis W, Bumpus N, et al. Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study. Lancet HIV. (2015) 2:e520–529. doi:10.1016/S2352-3018(15)00226-X

26. Spivak AM, Andrade A, Eisele E, Hoh R, Bacchetti P, Bumpus NN, et al. A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy. Clin Infect Dis. (2014) 58:883–90. doi:10.1093/cid/cit813

27. Vannessa T, Schmelz S, Brinkmann C, Wrightman F, Lewin SR, Melchjorsen J, et al. Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation. Hum Vaccin Immunother. (2013) 9:993–1001. doi: 10.4161/hv.23800

28. Spivak AM, Plantelles V. HIV-1 eradication: early trials (and Tribulations). Trends Mol Med. (2016) 22:10–27. doi:10.1016/j.tmm.2015.11.004

29. Van Lit C, Bouchat S, Marcello A. HIV-1 transcription and latency: an update. Retrovirology. (2013) 10:67. doi:10.1186/1742-4690-10-67

30. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, et al. HIV-1 transcription and latency: an update. Front Immunol. (2018) 9:128.876–89. doi:10.3389/fimmu.2018.00755

31. Kuo HH, Ahmad R, Lee GQ, Gao C, Chen HR, Ouyang Z, et al. Anti-apoptotic Protein BIRC5 Maintains Survival of HIV-1-Infected CD4(+) T Cells. Immunity. (2018) 48:1183–94.e1185. doi:10.1016/j.immuni.2018.04.004

32. Pollack RA, Jones RB, Pertea M, Bruner KM, Martin AR, Thomas AS, et al. PolyA/PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature. (2006) 443:350–4. doi:10.1038/nature05155

33. Ho YC, Shan L, Hosmane NN, Wang J, Laskey SB, Rosenblom DI, et al. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell. (2015) 155:540–51. doi:10.1016/j.cell.2013.09.020

34. Huang SH, Ren Y, Thomas AS, Chan D, Mueller S, Ward AR, et al. Latent HIV reservoirs exhibit inherent resistance to elimination by CD8(+) T cells. J Clin Invest. (2018) 128:876–89. doi:10.1172/JCI97555

35. Savva A, Roger T. Targeting toll-like receptors: promising therapeutic strategies for the management of sepsis-associated pathology and infectious diseases. Front Immunol. (2013) 4:387. doi: 10.3389/fimmu.2013.00387

36. Vannessa T, Galluzzi L, Eggermont A, Friman WH, Galon J, Sautes-Fridman C, et al. Trial Watch: toll-like receptor agonists for cancer therapy. Oncoimmunology. (2012) 1:e25238. doi:10.4161/onci.25238

37. Horscroft NJ, Pryde DC, Bright H. Antiviral applications of Toll-like receptor agonists. J Antimicrob Chemother. (2012) 67:789–801. doi:10.1093/jac/dkr588

38. Hankock RE, Nijnik A, Philpott DJ. Modulating immunity as a therapy for bacterial infections. Nat Rev Microbiol. (2012) 10:243–54. doi:10.1038/nrmicro2745

39. Galluzzi L, Vacchelli E, Eggermont A, Friman WH, Galon J, Sautes-Fridman C, et al. Trial Watch: experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology. (2012) 1:699–716. doi:10.4161/onci.20696

40. Savva A, Roger T. Targeting toll-like receptors: promising therapeutic strategies for the management of sepsis-associated pathology and infectious diseases. Front Immunol. (2013) 4:387. doi:10.3389/fimmu.2013.00387

41. Vacchelli E, Galluzzi L, Eggermont A, Friman WH, Galon J, Sautes-Fridman C, et al. Trial Watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncoimmunology. (2012) 1:894–907. doi:10.4161/onci.20931

42. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. (2010) 11:373–84. doi:10.1038/ni.1863

43. Kumar H, Kawai T, Akira S. Pathogen recognition by the innate immune system. Int Rev Immunol. (2011) 30:16–34. doi:10.3109/09882830.185.2010.529976

44. Schnare M, Holt AC, Takeda K, Akira S, Medzhitov R. Recognition of CpG DNA is mediated by signaling pathways dependent on the adaptor protein MyD88. Curr Biol. (2000) 10:1139–42. doi:10.1016/S0960-9822(00)00700-4

45. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol. (2007) 81:1–5. doi:10.1189/jlb.0306164

46. Vannessa T, Eggermont A, Bianchi ME. DAMPs from cell death to new life. Front Immunol. (2015) 4:622. doi:10.3389/fimmu.2015.00422

47. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. (2006) 125:783–801. doi:10.1016/j.cell.2006.02.015

48. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev. (2004) 4:499–511. doi:10.1038/nri1391

49. Oznisky A, Underhill DM, Fontenot JD, Hajjar AM, Smith KD, Wilson CB, et al. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. Proc Natl Acad Sci USA. (2000) 97:13766–71. doi:10.1073/pnas.250746977

50. Kang JY, Nan J, Jin MS, Youn SJ, Ryu YH, Mah S, et al. Recognition of lipopeptide patterns by Toll-like receptor 2-Toll-like receptor 6 heterodimer. Immunity. (2009) 31:873–84. doi:10.1016/j.immuni.2009.09.018

51. Takeuchi O, Kawai T, Muhlradt PF, Mör M, Radolf JD, Zychlinsky A, et al. Discrimination of bacterial lipopeptides by Toll-like receptor 6. Int Immunol. (2001) 13:933–40. doi:10.1093/intimm/13.7.933

52. Jin MS, Kim SE, Heo JY, Lee ME, Kim HM, Paik SG, et al. Crystal structure of the Toll1–TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. Cell. (2007) 130:1671–82. doi:10.1016/j.cell.2007.09.008

53. Means TK, Lien E, Yoshimura A, Wang S, Golenbock DT, Fenton MJ. The CD14 ligands liporabinomannan and lipopolysaccharide differ in their requirement for Toll-like receptors. J Immunol. (1999) 163:6748–55.

54. Rounds JL, Lee SM, Li J, Tran G, Jabri B, Chatila TA, et al. The Toll-like receptor 2 pathway establishes colonization by a commensal of
the human microbiota. *Science.* (2011) 332:974–7. doi: 10.1126/science.1206995

65. Gartner BN, Simmons RM, Canavera SJ, Akira S, Underhill DM. Collaborative induction of inflammatory responses by dectin-1 and Toll-like receptor 2. *J Exp Med.* (2003) 197:1107–17. doi: 10.1084/jem.20021787

66. Poltorak A, He X, Smirnova L, Liu MY, Van Huffel C, Du X, et al. Defective LPS signaling in C3H/HeJ and C57Bl/10ScCr mice: mutations in Tlr4 gene. *Science.* (1998) 282:2085–8. doi: 10.1126/science.282.5396.2085

67. Chow JC, Young DW, Golenbock DT, Christ WJ, Gusovsky F. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. *J Biol Chem.* (1999) 274:10689–92. doi: 10.1074/jbc.274.16.10689

68. Shimazu R, Akashi S, Ogata H, Nagai Y, Fukudome K, Miyake K, et al. Toll-like receptor 2. *J Exp Med.* (1999) 189:1777–82. doi: 10.1084/jem.189.11.1777

69. Hayashi F, Smith KD, Ozinsky A, Hawrn TR, Yi EC, Goodlett DR, et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. *Nature.* (2001) 410:1099–103. doi: 10.1038/35074110

70. Chuang T, Ulevitch RJ. Identification of hTLR10: a novel human Toll-like receptor preferentially expressed in immune cells. *Biochim Biophys Acta.* (2001) 1518:157–61. doi: 10.1016/S0167-4781(00)00289-X

71. Guan Y, Ranao DR, Jiang S, Murtha SK, Li X, Baudry J, et al. Human TLRs 10 and 1 share common mechanisms of innate immune sensing but not signaling. *J Immunol.* (2010) 184:5094–103. doi: 10.4049/jimmunol.0901888

72. Oosting M, Cheng SC, Bolscher JM, Vestering-Stenger R, Plantinga TS, Verschueren IC, et al. Human TLR10 is an anti-inflammatory pattern-recognition receptor. *Proc Natl Acad Sci USA.* (2014) 111:E4784–8. doi: 10.1073/pnas.140293111

73. Henrick BM, Yao XD, Zahoor MA, Abinuiku A, Osawe S, Rosenthal KL. TLR10 senses HIV-1 proteins and significantly enhances HIV-1 infection. *Front Immunol.* (2019) 10:482. doi: 10.3389/fimmu.2019.00482

74. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. *Nat Immunol.* (2002) 3:675–80. doi: 10.1038/nature02485

75. Alexopoulos L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. *Nature.* (2001) 413:732–8. doi: 10.1038/35099560

76. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. *Science.* (2004) 303:1526–9. doi: 10.1126/science.1093620

77. Hemmi H, Takeuchi O, Kawai T, Sanjo H, et al. A Toll-like receptor recognizes bacterial DNA. *Nat Immunol.* (2000) 4:870–5. doi: 10.1038/35074106

78. Ho NL, Huis In ’t Veld LGM, Raaijmakers TK, Adema GJ. Adjuvants enhancing cross-presentation by dendritic cells: the key to more effective vaccines? *Front Immunol.* (2018) 9:2874. doi: 10.3389/fimmu.2018.02874

79. Smith M, Garcia-Martinez E, Pitter MR, Fucikova J, Spisek R, Zitvogel L, et al. Trial Watch: toll-like receptor 3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. *J Transl Med.* (2007) 5:10. doi: 10.1186/1479-5876-5-10

80. Ulrich JT, Myers KR. Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. *Pharm Biotechnol.* (1995) 6:495–524. doi: 10.1007/978-1-4615-1823-5_21

81. Johnson DA, Sowel CC, Johnson CL, Livesay MT, Keegan DS, Rhodes MJ, et al. Synthesis and biological evaluation of a new class of vaccine adjuvants: aminoolkyl glucosaminide 4-phosphates (AGPs). *Biorg Med Chem Lett.* (1999) 9:2273–8. doi: 10.1016/S1050-9626(99)00374-1

82. Thompson BS, Chilton PM, Ward JR, Evans JT, Mitchell TC. The low-toxicity versions of LPS, MPL adjuvant and RC529, are efficient adjuvants for CD4+ T cells. *J Leukoc Biol.* (2005) 78:1273–80. doi: 10.1189/jlb.0503157

83. Toussi DN, Massari P. Immune adjuvant effect of molecularly-defined toll-like receptor ligands. *Vaccines.* (2014) 2:323–53. doi: 10.3390/vaccines20200323

84. Zaffaroni L, Peri F. Recent advances on Toll-like receptor 4 modulation: new therapeutic perspectives. *Future Med Chem.* (2018) 10:461–76. doi: 10.4115/fmc-2017-0172

85. Burdelga LG, Krivokrysenko VL, Tallant TC, Strom E, Gleiberman AS, Gupta D, et al. An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. *Science.* (2008) 320:226–30. doi: 10.1126/science.1154986

86. Fukuzawa N, Petro M, Baldwin WM III, Goddav K, Fairchild RL. A TLR5 agonist inhibits acute renal ischemic failure. *J Immunol.* (2011) 187:3831–9. doi: 10.4049/jimmunol.1002323

87. Mizel SB, Bates JT. Flagellin as an adjuvant: cellular mechanisms and potential. *J Immunol.* (2010) 185:5677–82. doi: 10.4049/jimmunol.1002156

88. Yuon SJ, Kurnasov O, Natarajan V, Hong M, Goddav K, Osterman AL, et al. Structural basis of TLR5-flagellin recognition and signaling. *Science.* (2012) 335:859–64. doi: 10.1126/science.1215584

89. Lee J, Chuang TH, Redecke V, She L, Pitta PM, Carson DA, et al. Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of Toll-like receptor 7. *Proc Natl Acad Sci USA.* (2003) 100:6646–51. doi: 10.1073/pnas.0631696100

90. Gorden KB, Gorski KS, Gibson SJ, Kelll RM, Kieper WC, Qiu X, et al. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. *J Immunol.* (2005) 174:1259–68. doi: 10.4049/jimmunol.174.3.1259

91. Kalali BN, Kollisch G, Mages J, Muller T, Bauer S, Wagner H, et al. Double-stranded RNA induces an antiviral defense status in epidermal keratinocytes through TLR3-, PKR-, and MDA5/RIG-1-mediated differential signaling. *J Immunol.* (2008) 181:2694–704. doi: 10.4049/jimmunol.181.4.2694

92. Ahonen CL, Gibson SJ, Smith RM, Pederson LK, Lindh JM, Tomai MA, et al. Dendritic cell maturation and subsequent enhanced T-cell stimulation induced with the novel synthetic immune response modifier R-848. *Cell Immunol.* (1999) 197:62–72. doi: 10.1006/cimm.1999.1555

93. Petricevic B, Wessner B, Sachet M, Vrbanec D, Spittler A, Bergmann M. CL097, a TLR7/8 ligand, inhibits TLR4–dependent activation
of IRAK-M and BCL-3 expression. Shock. (2009) 32:484–90. doi: 10.1097/SHK.0b013e3181a5c8a

105. Spranger S, Javorovic M, Burdek M, Wilde S, Mosetter B, Tippmer S, et al. Generation of Th1-polarizing dendritic cells using the TLR7/8 agonist CL075. J Immunol. (2010) 185:7534–7. doi: 10.4049/jimmunol.20090960

106. Pope BL, Chourmouzis E, Sigindere J, Capetola RJ, Lau CY. In vivo enhancement of murine natural killer cell activity by 7-allyl-8-oxoguanosine (loxoribine). Int Immunopharmacol. (1999) 12:1475–82. doi: 10.1016/S13890691(99)00089-9

107. Bergmann JF, de Bruijn J, Hotho DM, de Knecht RJ, Bonnstra A, Weegink CJ, et al. Randomised clinical trial: anti-viral activity of ANA737, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV. Aliment Pharmacol Ther. (2011) 34:443–53. doi: 10.1111/j.1365-2036.2011.04745.x

108. Xiang AX, Webber SE, Kerr MM, Lennox JR, Golenbock DT, Mansell MA, et al. Prevention of autoimmune disease by induction of tolerance to Toll-like receptor 7. Proc Natl Acad Sci USA. (2009) 106:2764–9. doi: 10.1073/pnas.0813037106

109. Hilbert T, Steinhagen F, Weihe C, Baumgarten G, Hoefl A, Klaschk S. Synergistic stimulation with different TLR7 ligands modulates gene expression patterns in the human plasmacytoid dendritic cell line CAL-1. Mediators Inflamm. (2015) 2015:948540. doi: 10.1155/2015/948540

110. Hayashi T, Gray CS, Chan M, Tawatao RI, Ronacher L, McGargill CJ, et al. Randomised clinical trial: anti-viral activity of GS-9620 dependent TLR7 activation. PLoS ONE. (2016) 11:e0146835. doi: 10.1371/journal.pone.0146835

111. Liu Y, Luo X, Yang C, Yu S, Xu H. Three CpG oligodeoxynucleotide classes differentially enhance antigen-specific humoral and cellular immune responses in mice. Vaccine. (2011) 29:5778–84. doi: 10.1016/j.vaccine.2011.05.087

112. Volkmann S, Winter S, Pareyte P, Jurk M, Schetter C, Laucht M, et al. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol. (2004) 34:2521–62. doi: 10.1002/eji.2003420302

113. Agrawal S, Kandimalla ER. Synthetic agonists of Toll-like receptors 7, 8 and 9. Biochem Soc Trans. (2007) 35:1461–7. doi: 10.1042/BST0351461

114. Paul S. Technology evaluation: CpG-7909, Coley. Curr Opin Mol Ther. (2003) 5:533–9.

115. Vicari AP, Schmalbach T, Lekstrom-Himes J, Morris ML, Al-Adhami MJ, Bentwich Z, Maertens G, Torten D, Lal AA, Lal RB. Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol. (1996) 157:1271–8.

116. Vicari AP, Schmalbach T, Lekstrom-Himes J, Morris ML, Al-Adhami MJ, Bentwich Z, Maertens G, Torten D, Lal AA, Lal RB. Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol. (1996) 157:1271–8.

117. Goletti D, Weissman D, Jackson RW, Graham NM, Vlahov D, Klein RS, et al. Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol. (1996) 157:1271–8.

118. Vicari AP, Schmalbach T, Lekstrom-Himes J, Morris ML, Al-Adhami MJ, Bentwich Z, Maertens G, Torten D, Lal AA, Lal RB. Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol. (1996) 157:1271–8.

119. Vicari AP, Schmalbach T, Lekstrom-Himes J, Morris ML, Al-Adhami MJ, Bentwich Z, Maertens G, Torten D, Lal AA, Lal RB. Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol. (1996) 157:1271–8.

120. Vicari AP, Schmalbach T, Lekstrom-Himes J, Morris ML, Al-Adhami MJ, Bentwich Z, Maertens G, Torten D, Lal AA, Lal RB. Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol. (1996) 157:1271–8.

121. Vicari AP, Schmalbach T, Lekstrom-Himes J, Morris ML, Al-Adhami MJ, Bentwich Z, Maertens G, Torten D, Lal AA, Lal RB. Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol. (1996) 157:1271–8.

122. Vicari AP, Schmalbach T, Lekstrom-Himes J, Morris ML, Al-Adhami MJ, Bentwich Z, Maertens G, Torten D, Lal AA, Lal RB. Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol. (1996) 157:1271–8.

123. Vicari AP, Schmalbach T, Lekstrom-Himes J, Morris ML, Al-Adhami MJ, Bentwich Z, Maertens G, Torten D, Lal AA, Lal RB. Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol. (1996) 157:1271–8.

124. Vicari AP, Schmalbach T, Lekstrom-Himes J, Morris ML, Al-Adhami MJ, Bentwich Z, Maertens G, Torten D, Lal AA, Lal RB. Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol. (1996) 157:1271–8.

125. Vicari AP, Schmalbach T, Lekstrom-Himes J, Morris ML, Al-Adhami MJ, Bentwich Z, Maertens G, Torten D, Lal AA, Lal RB. Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol. (1996) 157:1271–8.

126. Vicari AP, Schmalbach T, Lekstrom-Himes J, Morris ML, Al-Adhami MJ, Bentwich Z, Maertens G, Torten D, Lal AA, Lal RB. Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol. (1996) 157:1271–8.

127. Vicari AP, Schmalbach T, Lekstrom-Himes J, Morris ML, Al-Adhami MJ, Bentwich Z, Maertens G, Torten D, Lal AA, Lal RB. Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol. (1996) 157:1271–8.

128. Vicari AP, Schmalbach T, Lekstrom-Himes J, Morris ML, Al-Adhami MJ, Bentwich Z, Maertens G, Torten D, Lal AA, Lal RB. Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol. (1996) 157:1271–8.

129. Vicari AP, Schmalbach T, Lekstrom-Himes J, Morris ML, Al-Adhami MJ, Bentwich Z, Maertens G, Torten D, Lal AA, Lal RB. Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol. (1996) 157:1271–8.
144. Gonzalez OA, Li M, Ebersole JL, Huang CB. HIV-1 reactivation induced by the periodontal pathogens *Fusobacterium nucleatum* and *Porphyromonas gingivalis* involves Toll-like receptor 2 [corrected] and 9 activation in monocytes/macrophages. *Clin Vaccine Immunol.* (2010) 17:1417–27. doi: 10.4049/cvi.v17.i7.27

145. Nordone SK, Ignacio GA, Su L, Sempowski GD, Golenbock DT, Li L, et al. Failure of TLR4-driven NF-kappa B activation to stimulate virus replication in models of HIV type 1 activation. *AIDS Res Hum Retroviruses.* (2007) 23:1387–95. doi: 10.1089/aid.2007.0033

146. Novis CL, Arpin CM, Buzon MJ, Verdin E, Round JL, Lichterfeld J, et al. Development of disease and virus recovery in transgenic mice containing HIV-1 proviral DNA. *Science.* (1988) 242:1665–70. doi: 10.1126/science.3201255

147. Doherty TM, Chougnet C, Schito M, Patterson BK, Fox C, Shearer GM, et al. Infection of HIV-1 transgenic mice with *Mycobacterium avium* induces the expression of infectious virus selectively from a Mac-1-positive host cell population. *J Immunol.* (1999) 163:1506–15.

148. Gazzinelli RT, Sher A, Cheever A, Gerstberger S, Martin MA, Dickie P. Infection of human immunodeficiency virus 1 transgenic mice with *Toxoplasma gondii* stimulates proviral transcription in macrophages in vivo. *J Exp Med.* (1996) 183:1645–55. doi: 10.1084/jem.183.4.1645

149. Scheller C, Ulrich A, Lamla S, Dittmer U, Rethwilm A, Koutsilieri E. Dual activity of phosphorothioate CpG oligodeoxynucleotides on HIV: reactivation of latent provirus and inhibition of productive infection in human T cells. *Ann N Y Acad Sci.* (2006) 1091:540–7. doi: 10.1196/annals.1378.095

150. Scheller C, Ulrich A, McPherson K, Hefele B, Kneefler J, Lamla S, et al. CpG oligodeoxynucleotides activate HIV replication in latently infected human T cells. *J Biol Chem.* (2004) 279:21897–902. doi: 10.1074/jbc.M311690200

151. Offersen R, Nissen SK, Rasmussen TA, Ostergaard L, DNA, Sogaard OS, et al. A novel toll-like receptor 9 agonist. *MGN1703, enhances HIV-1 transcription and NK cell-mediated inhibition of HIV-1-infected autologous CD4+ T cells.* *J Virol.* (2016) 90:4451–53. doi: 10.1128/JVI.00222-16

152. Macedo AB, Resop RS, Martins LJ, Szaniawski MA, Sorensen ES, Spivak KM, et al. GS-9620 in the Woodchuck model of chronic hepatitis B. *Antivir Ther.* (2015) 20:119. doi: 10.3851/IMP2548

153. Schulz RS, Desai A, et al. The TLR9 agonist MGN1703 triggers a potent type I interferon response in the sigmoid colon. *Food Immunol.* (2017) 28:7–22. doi: 10.1089/food.2016.0053

154. Gazzinelli RT, Sher A, Cheever A, Gerstberger S, Martin MA, Dickie P. 1. Infection of human immunodeficiency virus 1 transgenic mice with *Toxoplasma gondii* stimulates proviral transcription in macrophages in vivo. *J Exp Med.* (1996) 183:1645–55. doi: 10.1084/jem.183.4.1645

155. S. Proline-proline-glutamic acid (PPE) protein Rv1168c of *Mycobacterium tuberculosis* reactivates latent HIV-1 in T cells in vitro. *PLoS ONE.* (2013) 12:e0185162. doi: 10.1371/journal.pone.0185162

156. Jones RB, Mueller S, O'Connor R, Rimpel K, Sloan DD, Karel D, et al. A PKC activator in concert with prostratin for activation of silent HIV. *AIDS Res Hum Retroviruses.* (2017) 34:769–77. doi: 10.1089/aid.2018.0098

157. Hernandez N, Pineda-Cantu E, Esquivel M, et al. HIV: reactivation of latent provirus and inhibition of productive infection in an *in vitro* AIDS model of HIV infection. *AIDS.* (2018) 32:1468–77. doi: 10.1093/aid.ajy057

158. Palacios M, Del Prete GQ, Alvord WG, Li Y, Delege C, Nag M, Oswald K, et al. TLR7 agonist administration to SIV-infected macaques receiving early initiated ART does not induce plasma viremia. *JCI Insight.* (2019) 4:217717. doi: 10.1172/jci.insight.127717

159. Winckelmann AA, Munk-Petersen LK, Rasmussen TA, Melchjorsen J, Ejlholt T, Montefiori DC, et al. Administration of a Toll-like receptor 9 agonist decreases the proviral reservoir in virologically suppressed HIV-infected patients. *PLoS ONE.* (2013) 8:e62074. doi: 10.1371/journal.pone.0062074

160. Penfield RD, Guerra B, Chavez D, Giavedoni L, Hodara VL, Brasky KM, et al. GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. *Gastroenterology.* (2013) 144:1508–17. 1517.e101–10. doi: 10.1053/j.gastro.2013.02.003

161. Lopez-IN, C. W., Roman C., Ohmstede C., Hesselgesser J., et al. Safety, pharmacokinetics and pharmacodynamics of GS-9620, an oral Toll-like receptor 7 agonist. *Antivir Ther.* (2013) 18:409–18. doi: 10.3851/IMP2548

162. Menne S, Tumas DB, Liu KH, Thampi L, AlDephaithier D, Baldwin BH, et al. Supported efficacy and seroversion with the Toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis B. *J Hepatol.* (2015) 62:1237–45. doi: 10.1016/j.jhep.2014.12.026

163. Sogaard OS, Schonheyder HC, Bukh AR, Harboe ZB, Rasmussen TA, Ostergaard L, et al. Pneumococcal conjugate vaccination in persons with HIV: the effect of highly active antiretroviral therapy. *AIDS.* (2010) 24:1315–22. doi: 10.3851/0032-3833/0178

164. Krupar AP, Abdel-Mohsen M, Schleimann MH, Vibholm L, Engen PA, et al. Development of disease and virus recovery in transgenic mice containing HIV-1 proviral DNA. *Cell Immunol.* (2010) 264:1–10. doi: 10.1016/j.cellimm.2009.10.006

165. Fujimoto C, Nakagawa Y, Ohara K, Takahashi H. Polyribosinic acid: polyricinic acid [*poly*(I:C)]/TLR3 signaling allows class 1 processing of exogenous protein and induction of HIV-specific CD8+ cytotoxic T lymphocytes. *Int Immunol.* (2004) 16:55–63. doi: 10.1093/intimm/dxh025
Bam RA, Hansen D, Irrinki A, Mulato A, Jones GS, Hesselgesser J, et al. TLR7 agonist GS-9620 is a potent inhibitor of acute HIV-1 infection in human peripheral blood mononuclear cells. *Antimicrob Agents Chemother.* (2017) 61:e01369-16. doi: 10.1128/AAC.01369-16

Wille-Reece U, Wu CY, Flynn BJ, Kedl RM, Seder RA. Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses. *J Immunol.* (2005) 174:7676–83. doi: 10.1128/JI.01256-04

Schlaepfer E, Speck RF. Anti-HIV activity mediated by natural killer and CD8+ cells after toll-like receptor 7/8 triggering. *PLoS ONE.* (2008) 3:e1999. doi: 10.1371/journal.pone.0001999

Tomescu C, Chehimi J, Maino VC, Montaner LJ. NK cell lysis of HIV-1-infected autologous CD4 primary T cells: requirement for IFN-mediated NK activation by plasmacytoid dendritic cells. *J Immunol.* (2007) 179:2097–104. doi: 10.4049/jimmunol.179.4.2097

Lore K, Betts MR, Brenchley JM, Kuruppu J, Khojasteh S, Perfetto S, et al. Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus- and HIV-1-specific T cell responses. *J Immunol.* (2003) 171:4320–8. doi: 10.4049/jimmunol.171.8.4320

Mukherjee S, Huda S, Sinha Babu SP. Toll-like receptor polymorphism in host immune response to infectious diseases: a review. *Scand J Immunol.* (2019) 90:e12771. doi: 10.1111/sji.12771

Skevaki C, Pararas M, Kostelidou K, Tsakris A, Routsias JG. Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious diseases. *Clin Exp Immunol.* (2015) 180:165–77. doi: 10.1111/cei.12578

Lafont S, Rouquie N, Azar P, Seillet C, Plumas J, Aspod C, et al. X-Chromosome complement and estrogen receptor signaling independently contribute to the enhanced TLR7-mediated IFN-alpha production of plasmacytoid dendritic cells from women. *J Immunol.* (2014) 193:5444–52. doi: 10.4049/jimmunol.1303400

Meier A, Chang JJ, Chan ES, Pollard RB, Sidhu HK, Kulkarni S, et al. Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1. *Nat Med.* (2009) 15:955–9. doi: 10.1038/nm.2004

Belmonte L, Olmos M, Fanin A, Parodi C, Bare P, Concetti H, et al. The intestinal mucosa as a reservoir of HIV-1 infection after successful HAART. *AIDS.* (2007) 21:2106–8. doi: 10.1097/QAD.0b013e3282fe74b

Lamers SL, Rose R, Maidji E, Agsalda-Garcia M, Nolan DJ, Fogel GB, et al. HIV DNA is frequently present within pathologic tissues evaluated at autopsy from combined antiretroviral therapy-treated patients with undetectable viral loads. *J Virol.* (2016) 90:8968–83. doi: 10.1128/JVI.00674-16

Licht A, Alter G. A Drug-Free Zone–Lymph Nodes as a Safe Haven for HIV. *Cell Host Microbe.* (2016) 19:275–6. doi: 10.1016/j.chom.2016.02.018

Rose R, Nolan DJ, Maidji E, Stoddart CA, Singer EJ, Lamers SL, et al. Eradication of HIV from tissue reservoirs: challenges for the cure. *AIDS Res Hum Retroviruses.* (2018) 34:3–8. doi: 10.1089/aid.2017.0072

Yukl SA, Shergill AK, Ho T, Killian M, Girling V, Eppling L, et al. The distribution of HIV DNA and RNA in cell subsets differs in gut and blood of HIV-positive patients on ART: implications for viral persistence. *J Infect Dis.* (2013) 208:1212–20. doi: 10.1093/infdis/jit308

McNamara LA, Ganesh JA, Collins KL. Latent HIV-1 infection occurs in multiple subsets of hematopoietic progenitor cells and is reversed by NF-kappaB activation. *J Virol.* (2012) 86:9337–50. doi: 10.1128/JVI.00895-12

Khouri G, Darcis G, Lee MY, Bouchat S, Van Driessche B, Purcell DFJ, et al. The molecular biology of HIV latency. *Adv Exp Med Biol.* (2018) 1075:187–212. doi: 10.1007/978-981-13-0484-2_8

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Macedo, Novis and Bosque. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.